Adjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials
Adjuvant NSAID therapy is associated with improved DFS in patients with PIK3CA-mutated CRC. OS benefit remains uncertain, and findings from sensitivity analyses are exploratory. These findings support consideration of NSAIDs as a biomarker-informed adjuvant strategy in selected patients while underscoring the need for confirmatory evidence from ongoing randomized trials.
Authors
- Filipe Visani (ORCID: https://orcid.org/0009-0007-7884-5969)
- Caio Dabbous de Liz
- H. C. Brito (ORCID: https://orcid.org/0009-0005-2624-3486)
- Ellen R. Blanchard-Cavagis
- Pedro C. Abrahão Reis
- Isabela C. Diniz
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Universidade Estadual de Maringá (BR)
- Universidade Federal da Paraíba (BR)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Centro de Pesquisas Oncológicas (BR)
Publication Details
- Journal
- Critical Reviews in Oncology/Hematology
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1016/j.critrevonc.2026.105167
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00